Entity

Time filter

Source Type


Mediouni A.,Service de Medecine Nucleaire | Ammari S.,Service de Medecine Nucleaire | Wassef M.,Service de Cytologie et danatomie Pathologique | Wassef M.,University Paris Diderot | And 7 more authors.
European Annals of Otorhinolaryngology, Head and Neck Diseases | Year: 2014

Background The objective of this study was to report 11 cases of malignant head and neck paraganglioma and to compare their epidemiological, clinical, and genetic characteristics, their natural history and their treatment with those of a series of 131 benign paragangliomas. Patients and methods Retrospective analysis of 142 patients with head and neck paraganglioma managed between 2001 and 2008. Age at the time of diagnosis, gender, primary tumour site, presence of other non-head/neck paragangliomas and/or metastases diagnosed by imaging (CT, MRI, Octreoscan or 18F-FDG PET), histology, urinary catecholamine and metanephrine levels, family history, and genetic test results were recorded. Results This series comprised 131 benign head and neck paragangliomas, mostly observed in women with a mean age at diagnosis of 45 years and a predominance of tympanojugular sites (followed by carotid and vagal sites) with 5% of secreting tumours and 20% of multifocal tumours. Eleven patients (7.7%) with a 1:1 sex ratio presented criteria of malignancy. These patients, with a lower mean age (38 years), predominantly presented carotid lesions with a higher rate of secreting and multifocal tumours, 27% and 46% respectively. The main sites of metastases were bone and lymph nodes. No tympanic paragangliomas were observed. Conclusions Malignant paragangliomas are mainly observed in young patients with multifocal tumours, particularly carotid tumours, and are predominantly related to subunit SDH-B mutation. The work-up in these high-risk patients must include whole body scintigraphy and spine MRI. Malignancy is not necessarily associated with a poor short-term prognosis due to the slow course of the disease. © 2013 Elsevier Masson SAS. Source


Ahlem B.,Service de Cytologie et danatomie Pathologique | Wided A.,Service de Cytologie et danatomie Pathologique | Amani L.,Service de Chirurgie Maxillo Faciale | Nadia Z.,Service de Cytologie et danatomie Pathologique | And 2 more authors.
European Annals of Otorhinolaryngology, Head and Neck Diseases | Year: 2015

Introduction: Ameloblastoma is a rare, benign, purely epithelial odontogenic tumour, characterized by ahigh potential for local invasion and recurrence.Objective: To study the epidemiological and histological characteristics of ameloblastoma. To study Ki67and CD10 immunostaining in ameloblastoma and to investigate a possible correlation between these twomarkers and recurrence of this tumour.Methods: An immunohistochemical study using Ki67 and CD10 monoclonal antibodies was performedon 37 paraffin blocks obtained from the Charles-Nicolle hospital pathology department in Tunis over a9-year period (2004-2012). Statistical analysis was performed with Statistical Package for Social Sciences(SPSS) software version 15.1.Results: This series of 37 cases comprised 21 males and 16 females (sex ratio: 1.3) with a mean age of 39years (range: 7 to 70 years), corresponding to 36 cases of intraosseous ameloblastoma and one case ofgingival ameloblastoma. Thirty-two cases were polycystic and 5 cases were unicystic. Eighteen cases oflocal recurrence were observed. No correlation was demonstrated between recurrence and the variousclinical and histological parameters and treatment modalities. However, a significant correlation wasdemonstrated between recurrence and Ki67 and CD10 expression (P = 0.000 and 0.002, respectively).Conclusion: The Ki67 proliferation index and stromal CD10 expression can be considered to be predictivefactors of ameloblastoma recurrence. © 2015 Elsevier Masson SAS. Source

Discover hidden collaborations